SUMMARY Twenty fibrositic patients were treated with imipramine 50-75 mg/day. Only two patients responded favourably. Nineteen patients stopped therapy during the initial three-month period: 14 of them due to lack of response, while two of these concomitantly disclosed side effects. The additional five patients stopped therapy mainly due to side effects, while only one of them improved with therapy. One patient, only, improved and adhered to therapy for more than three months.
Fibrositis is a chronic disease characterised by muscular aches with local point tenderness, stiffness, disturbed sleep, and normal laboratory and radiological results.1 Disturbance in non-REM (rapid eye movement) sleep The therapeutic trial consisted of imipramine at an initial dose of 25 mg twice a day. Fourteen days later when this dose was well tolerated it was raised to 25 mg three times a day.
Results
Twenty patients were examined: nineteen females and one male. The mean age of the patients was 46*9± 10-9 years, and the mean duration of the disease 7-2±6-5 years: less than one year in three Because of the open nature of our study it could be argued that some of the side effects are nonspecific, secondary to a placebo effect. Yet, the fact that most patients did not improve with therapy is unrelated to the nature of our study.
Our results confirm previous impressions of poor compliance and response of fibrositic patients to therapy. A review of the literature shows that there is a discrepancy between the extensive evaluation of the presentation, symptoms, and signs of fibrositis4 6 it) and the relatively limited evaluation Imipramine for the treatment of fibrositis 753 of therapy. This discrepancy might be attributed to the disturbed psychological profile of these patients, with pronounced hypochondriasis and hysteria, that could limit compliance in therapeutic trials. Future fibrositis investigation should focus on evaluating the efficacy of various therapeutic regimens.
The management of the rheumatic diseases may be the province of the rheumatologist, but he relies heavily on the skills of an increasing number of allied professions, including nurses, physiotherapists, occupational therapists, clinical metrologists, and medical social workers. This volume fulfils a clear need in that it reviews for the support specialist the whole field of rheumatic diseases and their management, covering all practical aspects and providing an integrated view of the work and specific skills of the various paramedical support specialists. The sections on clinical diseases and their investigation is brief but adequate, although the quality of some of the x-ray illustrations is poor. The chapters on treatment, nursing, and clinical assessment are excellent, clearly written, balanced in view, and practical. It is refreshing to find a section devoted to patient education. There is a useful index which, together with a detailed contents list, makes information retrieval easy. I would thoroughly recommend this book to any nonmedical specialist working in the field of rheumatic diseases.
Consultant Physician/Rheumatologist, Whipps Cross Hospital. London.
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